Glucocorticoid treatment in SLE is associated with infections, comorbidities, and mortality-a national cohort study.

Results highlight the potential harm associated with even low OCS dose treatment in SLE and the need to judiciously use OCS at the lowest possible dose to maximize efficacy and minimize harm.